Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
183
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 7 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | Zanubrutinib | FDA US | cancer not stated in this record | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be… | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be… | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | cancer not stated in this record | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be… | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be… | ORIGNDA218785 | approved | openfda |
| Jun 10, 2025 | Zanubrutinib | FDA US | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | ORIGNDA218785 | approved | openfda |
| Jun 6, 2025 | Zolbetuximab | FDA US | cancer not stated in this record | Efficacy supplement 2025-06-06 (see label) | SUPPLBLA761365 | approved | openfda |
| Jun 6, 2025 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-06-06 (see label) | SUPPLBLA125514 | approved | openfda |
| Jun 5, 2025 | Meloxicam | FDA US | cancer not stated in this record | XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.… | ORIGNDA218395 | approved | openfda |
| Jun 3, 2025 | Darolutamide | FDA US | cancer not stated in this record | Efficacy supplement 2025-06-03 (see label) | SUPPLNDA212099 | approved | openfda |
| Jun 3, 2025 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-06-03 (see label) | SUPPLBLA125514 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 23, 2025 | Palbociclib | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-23 (see label) | SUPPLNDA212436 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 28, 2025 | Durvalumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-03-28 (see label) | SUPPLBLA761069 | approved | openfda |
| Mar 26, 2025 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| May 23, 2025 | Ipilimumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-23 (see label) | SUPPLBLA125377 | approved | openfda |
| May 22, 2025 | Denosumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-22 (see label) | SUPPLBLA125320 | approved | openfda |
| May 22, 2025 | Roflumilast | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-22 (see label) | SUPPLNDA217242 | approved | openfda |
| May 22, 2025 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-22 (see label) | SUPPLBLA125514 | approved | openfda |
| May 22, 2025 | Leuprolide | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-22 (see label) | SUPPLNDA020263 | approved | openfda |
| May 22, 2025 | Carfilzomib | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-22 (see label) | SUPPLNDA202714 | approved | openfda |
| May 15, 2025 | Retifanlimab | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-15 (see label) | SUPPLBLA761334 | approved | openfda |
| May 14, 2025 | Trastuzumab Emtansine | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-14 (see label) | SUPPLBLA125427 | approved | openfda |
| May 14, 2025 | Belzutifan | FDA US | cancer not stated in this record | Efficacy supplement 2025-05-14 (see label) | SUPPLNDA215383 | approved | openfda |
| Apr 23, 2025 | Palbociclib | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-23 (see label) | SUPPLNDA207103 | approved | openfda |
| Apr 22, 2025 | Tislelizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-22 (see label) | SUPPLBLA761232 | approved | openfda |
| Apr 22, 2025 | Tislelizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-22 (see label) | SUPPLBLA761232 | approved | openfda |
| Apr 22, 2025 | Tislelizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-22 (see label) | SUPPLBLA761232 | approved | openfda |
| Apr 22, 2025 | Tislelizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-22 (see label) | SUPPLBLA761232 | approved | openfda |
| Apr 22, 2025 | Tislelizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-22 (see label) | SUPPLBLA761232 | approved | openfda |
| Apr 22, 2025 | Tislelizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-22 (see label) | SUPPLBLA761232 | approved | openfda |
| Apr 22, 2025 | Meloxicam | FDA US | cancer not stated in this record | QAMZOVA is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.… | ORIGNDA217593 | approved | openfda |
| Apr 21, 2025 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-21 (see label) | SUPPLBLA125514 | approved | openfda |
| Apr 15, 2025 | Belzutifan | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-15 (see label) | SUPPLNDA215383 | approved | openfda |
| Apr 15, 2025 | Belzutifan | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-15 (see label) | SUPPLNDA215383 | approved | openfda |
| Apr 11, 2025 | Nivolumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-11 (see label) | SUPPLBLA125554 | approved | openfda |
| Apr 11, 2025 | Ipilimumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-11 (see label) | SUPPLBLA125377 | approved | openfda |
| Apr 10, 2025 | Daratumumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-10 (see label) | SUPPLBLA761036 | approved | openfda |
| Apr 9, 2025 | Larotrectinib | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-09 (see label) | SUPPLNDA211710 | approved | openfda |
| Apr 9, 2025 | Larotrectinib | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-09 (see label) | SUPPLNDA210861 | approved | openfda |
| Apr 8, 2025 | Nivolumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-08 (see label) | SUPPLBLA125554 | approved | openfda |
| Apr 8, 2025 | Ipilimumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-08 (see label) | SUPPLBLA125377 | approved | openfda |
| Apr 7, 2025 | Ramucirumab | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-07 (see label) | SUPPLBLA125477 | approved | openfda |
| Apr 7, 2025 | Dexamethasone | FDA US | cancer not stated in this record | Efficacy supplement 2025-04-07 (see label) | SUPPLNDA208742 | approved | openfda |
| Cabozantinib |
| FDA US |
| cancer not stated in this record |
| Efficacy supplement 2025-03-26 (see label) |
| SUPPLNDA208692 |
| approved |
| openfda |
| Mar 25, 2025 | Denosumab | FDA US | cancer not stated in this record | of postmenopausal women with osteoporosis at high risk for fracture • to increase bone mass in men with osteoporosis at high risk for… | ORIGBLA761398 | approved | openfda |
| Mar 25, 2025 | Denosumab | FDA US | Malignant Breast Neoplasm | to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer | ORIGBLA761398 | approved | openfda |